7th Urologic Oncology: Advances in Clinical Practice
7th Urologic Oncology: Advances in Clinical PracticeNovember 2-3, 2012MD Anderson, Dan L. Duncan BuildingConference Center, Floor 81155 Pressler StreetHouston, TexasNursing Session – November 2, 2012Urologic Oncology: Nursing Advances in Clinical PracticeMD Anderson, Dan L. Duncan BuildingConference Center, Floor 81155 Pressler StreetHouston, TexasFocusThe 7th Urologic Oncology Conference will focus on the diagnosis, treatment, clinical advances,and controversies in localized and advanced cancers of the bladder, prostate and kidney.Educational ObjectivesAfter attending the conference, participants should be able to• illustrate and implement clinical advances in the diagnosis and evaluation of bladder, prostate, and kidney cancers (knowledge, competence, performance, patient outcomes);• illustrate and implement clinical advances in the treatment approach to localized and locally advanced bladder, prostate and kidney cancers (knowledge, competence, performance, patient outcomes);• illustrate and implement clinical advances in the treatment approach to metastatic bladder, prostate and kidney cancers (knowledge, competence, performance, patient outcomes);• identify contemporary controversies in the management of bladder, prostate and kidney cancers (knowledge).Educational MethodsLectures – Case Presentations – Panel Discussions – Audience Response System – Questionand Discussion SessionsTarget AudienceThis conference should be of value to urologists, medical oncologists, nurses, nursepractitioners, and physician assistants.EvaluationA course evaluation form will provide participants with the opportunity to comment on the valueof the program content to their practice decisions, performance improvement activities, orpossible impact on patient health status. Participants will also have the opportunity to commenton any perceived commercial bias in the presentations as well as to identify future educationaltopics.
Accreditation/Credit DesignationPhysiciansThe University of Texas MD Anderson Cancer Center is accredited by the Accreditation Councilfor Continuing Medical Education to provide continuing medical education for physicians.The University of Texas MD Anderson Cancer Center designates this live activity for a maximumof 13.25 AMA PRA Category 1 Credits TM. Physicians should claim only the creditcommensurate with the extent of their participation in the activity.CME Certificates and Attendance Verification CertificatesCertificates awarding AMA PRA Category 1 Credit TM or certificates documenting attendance willbe distributed to participants as they depart the symposium. To obtain a CME certificate,physicians must submit a completed evaluation questionnaire and a CME Verification Form.Upon request, a record of attendance (certificate) will be provided on-site to other health careprofessionals for requesting credits in accordance with state nursing boards, specialty societies,or other professional associations.MD Anderson Organizing CommitteeConference ChairsChristopher G. Wood, MDProgram Co-ChairmanProfessor and Vice ChairmanUrologyNizar M. Tannir, MDProgram Co-ChairmanAssociate Professor and Vice ChairmanGenitourinary Medical OncologyConference CommitteeJames Cavalier, Jr., MBA, MSN, RN, CRRNNursing PlannerNursing Extramural ProgramsSeungtaek Choi, MDAssistant ProfessorRadiation OncologyGloria CurtisSenior Administrative AssistantGenitourinary Medical OncologyJohn Davis, MDAssistant ProfessorUrology
Silvestina DeCoteau, RN, BSN, MSN, NEANursing Program Co-ChairmanAssociate Director of Clinical NursingNursingCarol FourtuniaSenior Administrative AssistantUrologyDeborah Hooker, RN, MSN, BC, ACNPNursing Program Co-ChairmanAdvanced Practice NurseUrologyColleen HubonaDirector, Multidisciplinary Programs and ProjectsProgram Center – GenitourinaryJay Shah, MDAssistant ProfessorUrologyArlene Siefker-Radtke, MDAssociate ProfessorGenitourinary Medical OncologyJudi Williams, BSSenior Conference CoordinatorCME/Conference ManagementUrologic Oncology: Nursing Advances in Clinical PracticeFriday, November 2, 2012Accreditation/Credit DesignationNursing Continuing Education Contact Hours will be provided.The University of Texas MD Anderson Cancer Center is an approved provider of continuingnursing education by the Texas Nurses Association, an accredited approver by the AmericanNurses Credentialing Center’s Commission on Accreditation.Educational ObjectivesAfter attending this educational activity, participants should be able to• Describe the genitourinary anatomy in detail;• Identify patients who are candidates for PSA screening according to current guidelines and the new PSA controversy;• Discuss the treatment options and modalities offered to newly diagnosed prostate cancer patients through the Multidisciplinary Clinic;• Identify urothelial cancer patients who are surgical candidates, discuss their post-operative care management, and describe acute post-operative complications and intervention rationales;• Explain the psychological impact of urinary diversions/ostomies and discuss management;• Discuss treatment modalities for renal tumor observation versus surgery and explain the rationale for both;
• Describe the rationale and guidelines for the GU Cancer Survivorship Program and identify the patient benefits.Nursing Session Program7:30 am Registration and Continental Breakfast Poster Session8:00 Welcome and Opening Remarks Deborah Hooker, RN, MSN, BC, ACNP Nursing Program Co-Chairman8:05 Anatomical Review – Genitourinary System Irene Inguillo, RN, BSN8:15 Prostate Cancer Screening: Current Guidelines and PSA Controversies Deborah Hooker, RN, MSN, BC, ACNP9:00 Multidisciplinary Prostate Cancer Clinic: What are the treatment options? Lydia Madsen, RN, MSN, CNS9:45 Break and Poster Session10:00 Urothelial Cancer: Candidates for Surgical Intervention, Post-operative Care and Acute Post-operative Complications Silvestina DeCoteau, RN, BSN, MSN, NEA-BC; and Robert L. Massey, PhD, MS, RN, BSN, NEA-BC10:40 Psychological Impact and Management of Urinary Diversion / Ostomy Cynthia Worley, RN, BSN, COCN, CWOCN11:00 Renal Tumor Treatment Modalities: Surgery vs. Observation Reena Cherry, PA-C, MS11:45 Survivorship Clinic: Rationale and Benefits William Osai, RN, MSN, NP12:15 pm Closing Remarks and Evaluations Silvestina DeCoteau, RN, BSN, MSN, NEA-BC Nursing Program Co-ChairmanMD Anderson Nursing Session FacultyReena W. Cherry, PA-C, MSPhysician AssistantGenitourinary Medical OncologySilvestina DeCoteau, RN, BSN, MSN, NEA-BCAssociate Director of Clinical NursingNursingDeborah Hooker, RN, MSN, BC, ACNPAdvanced Practice NurseUrology
Irene A. Inguillo, RN, BSNClinical Nurse, OutpatientGU Center, Medical OncologyLydia T. Madsen, RN, MSN, CNSAdvanced Practice NurseGenitourinary Medical OncologyRobert L. Massey, PhD, MS, RN, BSN, NEA-BCAssistant ProfessorDepartment of NursingWilliam E. Osai, RN, MSN, NPAdvanced Practice NurseGenitourinary Medical OncologyCynthia A. Worley, RN, BSN, COCN, CWOCNWOC NurseNursing WOCGeneral Session ProgramFriday, November 2, 2012Noon Registration and General Session Attendee Lunch12:45 pm Welcome and Opening Remarks Christopher G. Wood, MD; and Nizar M. Tannir, MDSESSION I: UROTHELIAL CANCER Session Chairs: Jay B. Shah, MD; and Arlene Siefker-Radtke, MDSuperficial DiseaseModerator: Jay B. Shah, MD1:00 Basics of Superficial Disease and CIS: The MDACC Treatment Algorithm Jay B. Shah, MD1:10 Novel Approaches to Localized Bladder Cancer Colin Dinney, MD1:20 Controversy: T1 High Grade Disease: BCG vs. Cystectomy BCG is the Best Therapy Ashish Kamat, MD Immediate Cystectomy is the Best Therapy Colin Dinney, MDUpper Tract DiseaseModerator: Arlene Siefker-Radtke, MD1:40 Treatment of Superficial Upper Tract Transitional Cell Carcinoma Surena Matin, MD1:50 Role for Neoadjuvant Therapy and LND for Upper Tract Transitional Cell
Carcinoma Arlene Siefker-Radtke, MD2:00 Case Presentations: Superficial Bladder Cancer and Upper Tract Tumors Moderator: Jay B. Shah, MD Panelists: Colin Dinney, MD; Ashish Kamat, MD; Surena Matin, MD; and Arlene Seifker-Radtke, MD2:30 Questions and Discussion2:40 BreakTreatment of Advanced DiseaseModerator: Arlene Siefker-Radtke, MD3:00 Robotic Cystectomy John Davis, MD3:10 Bladder Replacement Options O. Lenaine Westney, MD3:20 Controversy: Extent of LND Debate Extended LND is Necessary H. Barton Grossman, MD Extended LND is not Necessary Jay Shah, MD3:40 Neoadjuvant Chemotherapy – the MDACC Treatment Paradigm Farshid Dayyani, MD, PhD3:50 Controversy: Is there a role for radiation in the curative management of bladder cancer? Yes, there is a role. Andrew Lee, MD No, there is not a role. Randall Millikan, MD, PhD4:10 Node Positive Urothelial Cancer: “When to snip, when to dip” Arlene Siefker- Radtke, MD4:20 Questions and Discussion4:30 Break4:45 Case Presentations in Bladder Cancer Moderator: Arlene Siefker-Radtke, MD Panelists: John Davis, MD; Farshid Dayyani, MD, PhD; Colin Dinney, MD; H. Barton Grossman, MD; Ashish Kamat, MD; Andrew Lee, MD; Randall Millikan, MD, PhD; Jay Shah, MD; and O. Lenaine Westney, MD5:30 Andrew C. von Eschenbach Lecture John Libertino, MD
Lahey Clinic6:15 pm Adjourn and ReceptionSaturday, November 3, 20127:00 am Registration and Breakfast8:00 Welcome and Opening Remarks Christopher Wood, MD; and Nizar M. Tannir, MD8:05 Distinguished Alumnus Presentation: Class of 2006 Wassim Kassouf, MDSESSION II: KIDNEY CANCER Session Chairs: Christopher G. Wood, MD; and Nizar M. Tannir, MDModerator: Christopher G. Wood, MDCase Presentation74 year old WM presents with incidental finding of a 3.5 cm incidental renal mass. Co-morbidities include HTN and Type II DM.WHAT IS THE BEST TREATMENT OPTION? 8:30 The Case for Partial Nephrectomy Jose Karam, MD 8:45 The Case for Thermal Ablation Kamran Ahrar, MD 9:00 The Case for Active Surveillance Surena Matin, MDCase Presentation55 year old WM presents with locally advanced right renal tumor with IVC thrombus up to thehepatic veins. Metastatic evaluation is negative.WHAT IS THE BEST TREATMENT OPTION? 9:15 The Role of Adjuvant and Neoadjuvant Therapy and The Role of Lymph Node Dissection in the Treatment of Kidney Cancer Christopher G. Wood, MD 9:45 Management of IVC Thrombi in Locally Advanced Renal Cell Carcinoma John Libertino, MD10:00 Questions and Discussion10:10 BreakModerator: Nizar M. Tannir, MDCase Presentation47 year old WF presents with locally advanced left renal primary and bilateral pulmonary
metastasesWHAT IS THE BEST TREATMENT OPTION?Controversy: The Role of Cytoreductive Nephrectomy in the Era of Targeted Therapy 10:25 Upfront Cytoreductive Nephrectomy is the Standard of Care Jose Karam, MD 10:40 Pre-surgical Therapy is a Better Standard of Care Christopher G. Wood, MD10:55 Immunotherapy for Metastatic Renal Cell Carcinoma: Where we have been and where we are headed. Eric Jonasch, MD11:10 Systemic Targeted Therapy in the Treatment of Metastatic Renal Cell Carcinoma: What is the right initial agent, and what to do at disease progression? Nizar M. Tannir, MD11:25 Stereotactic Radiosurgery for Metastatic Renal Cell Carcinoma: What are the outcomes? Stephen Settle, MD, PhD11:40 Questions and Discussion: Renal Case Presentations Moderators: Christopher G. Wood, MD; and Nizar M. Tannir, MD Panelists: Kamran Ahrar, MD; Eric Jonasch, MD; Jose A. Karam, MD; John Libertino, MD; and Surena Matin, MD;12:30 pm LunchSESSION III: PROSTATE CANCER Session Chairs: Seungtaek Choi, MD; and John W. Davis, MDModerator: John W. Davis, MD1:15 Topic: Screening / Detection for Prostate Cancer Discussants: John W. Davis, MD; Bob Evans, PA-C; and William J. Graeber, MD1:45 Topic: Low Grade / Volume Prostate Cancer – Treatment Options Discussants: Brian Chapin, MD; Andrew Lee, MD, MPH; Vikas Kundra, MD; Thomas Pugh, MD; and John Ward, MD2:30 Topic: High Risk / Locally Advanced Prostate Cancer – Treatment Options Discussants: Brian Chapin, MD; Paul Corn, MD; and Sean McGuire, MD, PhD3:15 Break3:30 Topic: Lymph Node Positive Prostate Cancer Discussants: Brian Chapin, MD; Karen Hoffman, MD; and Lance Pagliaro, MD4:00 Topic: Recurrent / Metastatic Disease Discussants: Ana Aparicio, MD; Brian Chapin, MD; and Seungtaek Choi, MD4:45 Case Presentations
Moderator: Seungtaek Choi, MD Panelists: Ana Aparicio, MD; Brian Chapin, MD; Paul Corn, MD; John Davis, MD; Lance Pagliaro, MD; and John Ward, MD5:30 pm Closing Remarks and Adjourn Christopher G. Wood, MDMD Anderson FacultyKamran Ahrar, MDDiagnostic RadiologyAna Aparicio, MDGenitourinary Medical OncologyBrian F. Chapin, MDUrologySeungtaek Choi, MDRadiation OncologyPaul Corn, MDGenitourinary Medical OncologyJohn Davis, MDUrologyFarshid Dayyani, MD, PhDGenitourinary Medical OncologyColin Dinney, MDUrologyRobert B. Evans, PA-CUrologyWilliam J. Graber, MDUrologyH. Barton Grossman, MDUrologyKaren Hoffman, MDRadiation OncologyEric Jonasch, MDGenitourinary Medical OncologyAshish Kamat, MDUrologyJose A. Karam, MDUrologyVikas Kundra, MD, PhDDiagnostic Radiology
Andrew Lee, MDRadiation OncologySurena Matin, MDUrologySean McGuire, MD, PhDRadiation OncologyRandall Millikan, MD, PhDGenitourinary Medical OncologyLance Pagliaro, MDGenitourinary Medical OncologyThomas Pugh, MDRadiation OncologyStephen Settle, MD, PhDRadiation OncologyJay B. Shah, MDUrologyArlene Siefker-Radtke, MDGenitourinary Medical OncologyNizar M. Tannir, MDGenitourinary Medical OncologyJohn F. Ward, MDUrologyO. Lenaine Westney, MDUrologyChristopher G. Wood, MDUrologyGuest FacultyAndrew C. von Eschenbach Lecture AwardeeJohn A. Libertino, MDChair, Institute of UrologyLahey Clinic Medical CenterProfessor of UrologyTufts UniversityBurlington, MassachusettsDistinguished AlumniWassim Kassouf, MDProgram DirectorMcGill Urology ResidencyAssistant ProfessorDepartment of Surgery
McGill University Health CenterMontreal, CanadaThe University of Texas MD Anderson Cancer Center has implemented a process wherebyeveryone who is in a position to control the content of an educational activity must disclose allrelevant financial relationships with any commercial interest that could potentially affect theinformation presented. MD Anderson also requires that all faculty disclose any unlabeled use orinvestigational use (not yet approved for any purpose) of pharmaceutical and medical deviceproducts. Specific disclosure will be made to the participants prior to the educational activity.Agendas are subject to change because we are always striving to improve the quality of youreducational experience. MD Anderson may substitute faculty with comparable expertise on rareoccasions necessitated by illness, schedule conflicts, and so forth.Photographing, audio taping and videotaping are prohibited.Registration InformationUrologic Oncology: Nursing Advances in Clinical PracticeOn-site registration opens at 7:30 am on Friday, November 2, 2012. The conference will begin at8:00 am and end at 12:15 pm on Friday, November 2, 2012.Those wishing to attend the general conference that begins on Friday, November 2, 2012 at 12:45pm and ends on Saturday, November 3, 2012 at 5:30 pm must pay an additional fee of $50.00.Please see the registration form for instructions.Urologic Oncology: Advances in Clinical PracticeOn-site registration opens at Noon on Friday, November 2, 2012. The conference will begin at12:45 pm on Friday, November 2, 2012 and adjourn on Saturday, November 3, 2012 at 5:30 pm.Advance registration is encouraged as space and materials are limited. Please see the registrationform for applicable fees.The full conference registration fee includes the tuition, syllabus, breakfasts, breaks, lunches, andreception.The deadline for advance registration is Friday, October 19, 2012.There are three ways to register:1. Mail to: CME/Conference Management – Unit 1381, The University of Texas MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-14392. Fax to: 713-794-17243. On-line at www.mdanderson.org/conferencesWe accept the following forms of payment: 1. Check (payable through U.S. banks only) 2. Money Order 3. Credit Cards (MasterCard, VISA, and American Express) 4. Cash (on-site registration only)When registering online a receipt/confirmation letter will be automatically e-mailed to the e-mailaddress you list on the registration form. If you register by fax or mail, a receipt/confirmation letterwill be sent to you within ten working days of receipt of your fee.Refund/Cancellation Policy: The registration fee, minus a $50 administrative handling fee, is
refundable if a written request is received on or before October 19, 2012. No refunds will begranted after that date. The request for a registration refund must include the tax identificationnumber of the company or institution if registration was paid by a company or institution check.The Department of CME/Conference Management reserves the right to cancel activities prior to thescheduled date, if low enrollment or other circumstances make it necessary. Each registrant will benotified by mail, e-mail, or at the phone or fax numbers given on the registration form. In case ofactivity cancellation, the liability of the Department of CME/Conference Management is limited to theregistration fee. CME/Conference Management will refund the full registration fee.The Department of CME/Conference Management reserves the right to limit the number ofparticipants in a program and is not responsible for any expenses incurred by an individual whoseregistration is not confirmed and for whom space is not available.Special AssistanceContact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.Accommodations • A block of rooms has been reserved for conference attendees at the Houston Marriott at the Texas Medical Center, 6580 Fannin Street, Houston, Texas. • Early hotel reservation is suggested. To make reservations, please call Marriott Reservations at 800-228-9290 and identify yourself as part of the Urologic Oncology MD Anderson Room Block group staying at the Houston Marriott at the Texas Medical Center. • The special meeting rate is $112.00 single or double occupancy. Please add 17% Texas State and local taxes. Reservations and deposits received after October 18, 2012 will be confirmed if space is available and at current hotel published guest room rates.Air TravelMD Anderson has a program with United Airlines for discounted air travel. For discounts, callyour travel professional or Uniteds MeetingWorks toll free at 800-468-7022. Outside of theUnited States, please call your local United Airlines Reservation Office. Mention Z Code: ZM6Mand Agreement Code: 488954.Ground Transportation (prices are subject to change and variable depending on location of conference) • Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU). • Taxicabs are available at an estimated cost for $50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport. • Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Houston Marriott at the Texas Medical Center for $27 one-way and $54 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at www.supershuttle.com. • Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Houston Marriott at the Texas Medical Center for $24 one-way and $48 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at www.supershuttle.com.Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity.Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.